Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|November 17, 2023

Distinguishing Between Different MDS Subtypes

An expert perspective on the variety of MDS subtypes is provided.

Episodes in this series

EP. 1 Myelodysplastic Syndrome (MDS) Overview

EP. 1 Myelodysplastic Syndrome (MDS) Overview

EP. 2 Distinguishing Between Different MDS Subtypes

EP. 2 Distinguishing Between Different MDS Subtypes

EP. 3 MDS-Related Complications Impacting Patient Quality of Life

EP. 3 MDS-Related Complications Impacting Patient Quality of Life

EP. 4 Economic Implications of MDS Management

EP. 4 Economic Implications of MDS Management

EP. 5 Examining Treatment Algorithms for MDS

EP. 5 Examining Treatment Algorithms for MDS

EP. 6 Growth Factor and Stem Cell Transplant Candidacy in MDS

EP. 6 Growth Factor and Stem Cell Transplant Candidacy in MDS

EP. 7 Novel Agents Contributing to Evolving MDS Therapy Strategies

EP. 7 Novel Agents Contributing to Evolving MDS Therapy Strategies

EP. 8 Benefits of Oral Therapies In MDS Treatment Adherence

EP. 8 Benefits of Oral Therapies In MDS Treatment Adherence

EP. 9 Adapting MDS Treatment Approach

EP. 9 Adapting MDS Treatment Approach

EP. 10 Novel Therapy Impact on Patient Quality of Life

EP. 10 Novel Therapy Impact on Patient Quality of Life

Video 11 - "Multidisciplinary Care Driving Effective MDS Treatment"

EP. 11 Multidisciplinary Care Driving Effective MDS Treatment

Video 12 - "Payor Considerations In MDS Management"

EP. 12 Payor Considerations In MDS Management

Video 12 - "Payor Considerations In MDS Management"

EP. 13 Navigating Insurance-Related Challenges Associated With MDS Treatment

Video 12 - "Payor Considerations In MDS Management"

EP. 14 Key Considerations Surrounding MDS Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis